Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 19, 2009, Pages 5807-5810

  Mahaney, Paige E ^a   Kim, Callain Y ^a   Coghlan, Richard D ^a   Cohn, Stephen T ^a   Heffernan, Gavin D ^a   Huselton, Christine A ^a   Terefenko, Eugene A ^a   Vu, An T ^a   Zhang, Puwen ^a   Burroughs, Kevin D ^a   Cosmi, Scott A ^a   Bray, Jenifer A ^a   Johnston, Grace H ^a   Deecher, Darlene C ^a   Trybulski, Eugene J ^a  

^a PFIZER INC   (United States)

Author keywords

Monoamine reuptake inhibitors; Norepinephrine reuptake inhibitors (NRI); Serotonin transporter; Vasomotor symptoms (VMS)

Indexed keywords

INDOLE; INDOLE DERIVATIVE; MONOAMINE REUPTAKE INHIBITOR; NORADRENALIN TRANSPORTER; PHENYL GROUP; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; HUMAN; HUMAN CELL; IC 50; NONHUMAN; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; HUMANS; INDOLES; MODELS, ANIMAL; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; RATS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 69949111764     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.07.050     Document Type: Article

References (20)

1. Blakely R.D., De Felice L.J., and Hartzell H. J. Exp. Biol. 196 (1994) 263-281
2. Nguyen T.T., and Amara S.G. J. Neurochem. 67 (1996) 645-655
3. Lankupalle J.D., Annamalai B., Samuvel D.J., Gether U., and Ramamoorthy S. J. Biol. Chem. 281 (2006) 23326-23340
4. Kumar V.N. Proc. Natl. Acad. Sci., Part B: Biol. Sci. 69 (2003) 507-524
5. Riedel W., Dorward P.K., and Korner P.I. Auton. Neurosci. 3 (1981) 525-533
6. Lahti H., Pyornila A., and Hissa R. Experientia 36 (1980) 1188
7. Panek D., and Dixon W. J. Pharmacol. Exp. Ther. 236 (1986) 646-652
8. Deecher, D.; Merchenthaler, I.; Leventhal, L.; Sipe, K.; O'Connor, L. PCT Int. Appl. 2004, 58p. WO2004035035A1. CAN140:350602.
9. Dubini A., Bosc M., and Polin V. J. Psychopharmacol. 11 (1997) 17-23
10. Ban T.A., Gaszner P., Aguglia E., Batista R., Castillo A., et al. Hum. Psychopharmacol. 13 (1998) S29-S39
11. Bymaster F.P., Katner J.S., Nelson D.J., Hemrick-Luecke S.K., Threlkeld P.J., Heiligenstein J.H., Morin S.M., Gehlert D.R., and Perry K.W. Neuropsychopharmacology 27 (2002) 699-711
12. Krell H.V., Leuchter A.F., Cook I.A., and Abrams M. Psychosomatics 46 (2005) 379-389
13. Bergan T. Can. J. Psychiatry 49 (2004) 499-500
14. Kim C.Y., Mahaney P.E., McConnell O., Zhang Y., Manas E., Ho D.M., Deecher D.C., and Trybulski E.J. Bioorg. Med. Chem. Lett. 19 (2009) 5029-5032
15. Reith M.E.A., Meisler B.E., Sershen H., and Lajtha A. Biochem. Pharmacol. 35 (1986) 1123-1129
16. Madras B.K., Fahey M.A., Borgman J., Canfield D.R., and Spealman R.D.J. Pharmacol. Exp. Ther. 251 (1989) 131-141
17. Mahaney P.E., Vu A.T., McComas C.C., Zhang P., Nogle L.M., Watta W.L., Sarkahian A., Leventhal L., Sullivan N.R., Uveges A.J., and Trybulski E.J. J. Med. Chem. 51 (2008) 4038
18. Katsuki T., and Sharpless K.B. J. Am. Chem. Soc. 102 (1980) 5974-5976
19. Vu A.T., Cohn S.T., Terefenko E.A., Moore W.J., Zhang P., Mahaney P.E., Trybulski E.J., Goljer I., Dooley R., Bray J.A., Johnston G.H., Leiter J., and Deecher D.C. Bioorg. Med. Chem. Lett. 19 (2009) 2464-2467
20. Mahaney P.E., Vu A.T., McComas C.C., Zhang P., Nogle L.M., Watts W.L., Sarkahian A., Leventhal L., Sullivan N.R., Uveges A.J., and Trybulski E.J. Bioorg. Med. Chem. 14 (2006) 8455-8466